Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia

Leukemia and Lymphoma

Volumn 56, Issue 8, 2015, Pages 2326-2330

  Chantepie, Sylvain P ^a   Reboursiere, Emilie ^a   Mear, Jean Baptiste ^a   Gac, Anne Claire ^a   Salaun, Veronique ^b   Benabed, Khaled ^a   Cheze, Stéphane ^a   Johnsonansah, Hyacinthe ^a   Macro, Margaret ^a   Vilque, Jean Pierre ^c   Reman, Oumedaly ^a  

^a University Hospitals   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c Francois Baclesse Cancer Institute   (France)

Author keywords

chemotherapeutic approaches; clinical results; Myeloid leukemias and dysplasias

Indexed keywords

ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; BUSULFAN; CD33 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CREATININE CLEARANCE; DRUG MEGADOSE; ERYTHROCYTE; FEMALE; FORCED EXPIRATORY VOLUME; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LAMINAR AIRFLOW; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOENCEPHALOPATHY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SALVAGE THERAPY; SEPTIC SHOCK; SURGICAL MORTALITY; THROMBOCYTE TRANSFUSION; WHOLE BODY RADIATION; ADOLESCENT; ADVERSE EFFECTS; AGED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; REMISSION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943408398     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.986478     Document Type: Article

References (31)

1. Breems DA, Van Putten WLJ, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukaemia in first relapse. J Clin Oncol 2005; 23: 1969-1978.
2. Fiegl M, Unterhalt M, Kern W, et al. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukaemia: a randomized trial of the AMLCG. Leukemia 2014; 28: 1001-1007.
3. Sarkozy C, Gardin C, Gachard N, et al. Outcome of older patients with acute myeloid leukaemia in first relapse. Am J Hematol 2013; 88: 758-764.
4. van Der Velden VH, Marvelde te JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukaemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.
5. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukaemia in first recurrence. Cancer 2005; 104: 1442-1452.
6. Chevallier P, Delaunay J, Turlure P, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukaemia. J Clin Oncol 2008; 26: 5192-5197.
7. Stone RM, Moser B, Sanford B, et al. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukaemia: Cancer and Leukaemia Group B study 19902. Leuk Res 2011; 35: 329-333.
8. Brethon B, Yakouben K, Oudot C, et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol 2008; 143: 541-547.
9. Specchia G, Pastore D, Carluccio P, et al. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukaemia patients: a single-centre experience. Ann Hematol 2007; 86: 425-428.
10. Piccaluga PP, Martinelli G, Rondoni M, et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004; 28: 987-990.
11. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukaemia. Cancer Chemother Pharmacol 2003; 51: 87-90.
12. Apostolidou E, Cortes J, Tsimberidou A, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukaemia. Leuk Res 2003; 27: 887-891.
13. Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33 + primary resistant or relapsed acute myeloid leukaemia. Leuk Res 2003; 27: 893-897.
14. Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukaemia. Cancer Chemother Pharmacol 2002; 50: 497-500.
15. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. J. Clin Oncol 2001; 19: 3244-3254.
16. Filanovsky K, Shvidel L, Shtalrid M. Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukaemia. J Clin Oncol 2010; 28: e115-e116; author reply e117-e118.
17. Fianchi L, Pagano L, Leoni F, et al. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukaemia. Ann Oncol 2008; 19: 128-134.
18. Jabbour E, Garcia-Manero G, Cortes J, et al. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukaemia, high-risk myelodysplastic syndrome, and blast-phase chronic myeloid leukaemia. Clin Lymphoma Myeloma Leuk 2012; 12: 244-251.
19. Taksin A-L, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukaemia: a prospective study of the alfa group. Leukemia 2007; 21: 66-71.
20. Farhat H, Reman O, Raffoux E, et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukaemia salvage in patients aged 50-70-year old: a phase study of the acute leukaemia French association. Am J Hematol 2012; 87: 62-65.
21. Prebet T, Etienne A, Devillier R, et al. Improved outcome of patients with low-and intermediate-risk cytogenetics acute myeloid leukaemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. Cancer 2011; 117: 974-981.
22. Pilorge S, Rigaudeau S, Rabian F, et al. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukaemia in late first relapse. Am J Hematol 2014; 89: 399-403.
23. Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508-1516.
24. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukaemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
25. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
26. Kohrt HE, Patel S, Ho M, et al. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukaemia: a single-centre experience. Am J Hematol 2010; 85: 877-881.
27. Trifilio S, Zhou Z, Altman J, et al. Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukaemia. Leuk Res 2013; 37: 872-876.
28. Fong CY, Grigoriadis G, Hocking J, et al. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukaemia at first relapse. Leuk Lymphoma 2013; 54: 336-341.
29. Lee ST, Jang JH, Suh HC, et al. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukaemia and high-risk myelodysplastic syndrome. Am J Hematol 2001; 68: 237-245.
30. Martin MG, Augustin KM, Uy GL, et al. Salvage therapy for acute myeloid leukaemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol 2009; 84: 733-737.
31. Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukaemia. Blood 1991; 77: 1894-1900.